biochemical relapse of prostate cancer research hub

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

This Phase II trial tests an immunotherapy combination for men whose prostate cancer might be returning. It combines a cancer vaccine with a specialised antibody. The study aims to see if training the body's immune system can safely destroy lingering prostate cancer cells and stop PSA levels from rising.